Sangamo Therapeutics, Inc. SGMOQ
0.14
(0.01)
(6.67%)
as of 25 Sep
- Market cap
- $41.9M
- P/E
- 0.0×
Follow SGMOQ
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(292.47%) | (474.34%) | (2,891.84%) | 1,755.72% | |
| (66.44%) | (107.67%) | (152.35%) | (168.79%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(352.35%) | (1,230.67%) | (2,790.10%) | 2,162.55% | |
Average Days of Receivables |
1.66 | 5.81 | 3.42 | 9.22 | |
Free Cash Flow per Share |
(0.15) | (0.25) | (0.35) | (0.23) | |
Free Cash Flow |
(38.86) | (76.51) | (97.94) | (90.46) | |
Capital Expenditures |
(2.96) | (0.35) | (0.73) | (0.11) | |
Piotroski F-Score |
4.00 | 2.00 | 2.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(61.95%) | (207.11%) | (1,455.21%) | (1,046.70%) | |
Accounts Receivable Turnover |
171.47 | 5.97 | 88.19 | 55.78 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | (0.01) | |
Research and Development Expense of Revenue |
127.89% | 319.11% | 284.87% | 327.67% | |
Selling, General and Administrative Expense of Revenue |
49.02% | 112.53% | 88.20% | 91.57% | |
Share Based Compensation of Revenue |
13.98% | 31.12% | 22.95% | 21.63% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.57 | 0.71 | 0.79 | 0.73 | |
Depreciation/Fixed assets |
0.53 | 0.55 | 0.69 | 0.64 | |
Capex/Depreciation |
(0.35) | (0.04) | (0.10) | (0.02) | |
Revenue per Share |
0.32 | 0.11 | 0.14 | 0.09 | |
Operating CF per Share |
(0.14) | (0.25) | (0.35) | (0.23) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.01 | 0.02 | 0.00 | |
Net Profit Margin |
(77.48%) | (327.37%) | (310.81%) | (356.89%) |
Columns are period end dates